The global mergers and acquisitions landscape is experiencing a defining moment. Across insurance, pharmaceuticals, mining, biotechnology, beauty, and consumer food, a new wave of strategic consolidation is underway — with companies deploying tens of billions of dollars to secure competitive advantages, enter high-growth markets, and future-proof their business models.
From insurance giants to biotech breakthroughs and haircare brands — here is your complete briefing on the biggest M&A moves reshaping global markets right now. Five Deals. ~$34 Billion. One Seismic Shift Across Industries.
Below are the top five M&A deals announced in the week ending March 29th, 2026. The data is curated from the Intellizence mergers & acquisitions Dataset.
| Acquiring Company | Acquired Company | Deal Size | |
|---|---|---|---|
| Corebridge Financial | Equitable Holdings | $22 billion | |
| Merck | Terns Pharmaceuticals | $6.7 billion | |
| Zijin Gold | Chifeng Jilong Gold Mining | $2.6 billion | |
| Gilead Sciences | Ouro Medicines | $2.2 billion | |
| Henkel | OLAPLEX | $1.4 billion |
Corebridge Financial acquires Equitable Holdings
Acquiring Company – Corebridge Financial
Acquired Company: Equitable Holdings
Combines Deal Size: $22 Billion
Industry: Financial Services
Corebridge Financial, the insurance and retirement solutions spinoff of AIG, has entered into a definitive merger agreement with Equitable Holdings, one of America’s largest financial services firms. The all-cash deal is valued at approximately $22 billion, making it the largest transaction in this wave of M&A activity and one of the most significant insurance sector mergers in years.
What’s at Stake
- Creates a dominant force in US retirement and insurance markets
- Combines Corebridge’s annuities and life insurance with Equitable’s wealth management and protection businesses
- Positions the combined entity to serve tens of millions of Americans planning for retirement
- Significant cost synergies expected from operational consolidation
Why This Deal Matters
With a growing demand for retirement income solutions, this merger creates a powerhouse at exactly the right time. The combined company will have the scale to compete on pricing, technology investment, and distribution — reshaping the competitive dynamics of America’s $30+ trillion retirement savings industry. For consumers, it could mean more integrated financial planning products under one roof.
Merck acquires Terns Pharmaceuticals
Acquiring Company – Merck
Acquired Company – Terns Pharmaceuticals
Deal Amount – $6.7 billion
Industry: Pharmaceutical
Global pharmaceutical giant Merck has agreed to acquire Terns Pharmaceuticals, a clinical-stage oncology company, in a deal worth $6.7 billion. Terns has been developing a portfolio of small-molecule therapies targeting cancer, including promising compounds in the thyroid hormone receptor beta agonist and other oncology pathways. The acquisition gives Merck direct access to Terns’ pipeline and scientific talent.
What’s at Stake
- Bolsters Merck’s oncology pipeline beyond its flagship Keytruda immunotherapy
- Provides access to differentiated small-molecule cancer drug candidates
- Strengthens Merck’s position as cancer treatments evolve beyond immunotherapy
- Strategic hedge as Keytruda faces future patent expiration
Why This Deal Matters
Merck’s acquisition is a clear signal that it is investing heavily to diversify its cancer drug portfolio. For oncology patients, deals like this accelerate the translation of cutting-edge science into approved therapies. For investors, it underscores that Big Pharma continues to see clinical-stage oncology acquisitions as the most reliable pipeline strategy.
Zijin Gold acquires control of Chifeng Jilong Gold Mining
Acquiring Company – Zijin Gold
Acquired Company – Chifeng Jilong Gold Mining
Deal Amount –$2.6 billion
Industry: Mining
China’s Zijin Mining Group — one of the world’s largest gold and copper producers — has acquired a controlling stake in Chifeng Jilong Gold Mining Co., a Chinese domestic gold producer, for approximately $2.6 billion. The deal consolidates two significant Chinese gold producers and expands Zijin’s already substantial gold reserves and production capacity.
What’s at Stake
- Strengthens Zijin’s position as a global top-tier gold mining company
- Consolidates Chinese gold production in a period of elevated gold prices
- Increases Zijin’s domestic reserve base and mining operational scale
- Reflects broader trend of Chinese mining consolidation driven by state strategy
Why This Deal Matters
With gold prices near historic highs and central banks globally increasing their gold reserves, acquiring proven gold assets has rarely been more strategically valuable. This deal also reflects China’s broader industrial policy of consolidating its natural resource champions into globally competitive enterprises.
Gilead Sciences acquires Ouro Medicines
Acquiring Company – Gilead Sciences
Acquired Company – Oura Medicines
Deal Amount – $2.2 billion
Industry: Biotechnology
Gilead Sciences has acquired Ouro Medicines, a biotechnology company specialising in T cell engager therapies for autoimmune diseases, for $2.2 billion. T cell engagers are a cutting-edge class of biologics that direct the immune system’s T cells to target and destroy disease-causing cells — a mechanism that has shown remarkable promise in both oncology and, more recently, autoimmune conditions.
What’s at Stake
- Expands Gilead’s pipeline into autoimmune disease, a multi-billion-dollar market
- Adds novel T cell engager technology platform to Gilead’s biologic capabilities
- Positions Gilead to compete with leaders in immunology such as AbbVie and Roche
- T cell engager technology could unlock entirely new treatment categories
Why This Deal Matters
Autoimmune diseases affect hundreds of millions globally, yet many patients are still inadequately treated by existing therapies. T cell engager technology moves beyond symptom management toward durable remission. Gilead, historically known for its antiviral expertise, is making a calculated pivot into immunology, signalling where it believes the next wave of transformative medicine will emerge.
Henkel acquires OLAPLEX
Acquiring Company – Henkel
Acquired Company – OLAPLEX
Deal Amount – $1.4 billion
Industry: Consumer Goods
German consumer goods and industrial adhesives giant Henkel has agreed to acquire OLAPLEX, the cult professional and consumer haircare brand best known for its bond-building hair treatment technology, for $1.4 billion. The acquisition adds a premium, scientifically-positioned brand to Henkel’s consumer beauty portfolio.
What’s at Stake
- Gives Henkel a premium hero brand with strong global consumer recognition
- OLAPLEX’s patented bond-building chemistry provides durable product differentiation
- Access to OLAPLEX’s loyal customer base across professional salons and retail
- Henkel can leverage distribution scale to grow OLAPLEX in new markets
Why This Deal Matters
The consumers continue to invest in hair health products even during economic downturns. OLAPLEX’s patented chemistry and cult status among stylists and consumers alike makes it a rare acquisition target: a brand with genuine scientific credibility and cultural resonance. For Henkel this acquisition dramatically upgrades the quality and appeal of its beauty portfolio.
Frequently Asked Questions
What is the Intellizence M&A Dataset?
The Intellizence M&A Dataset delivers curated, structured merger and acquisition signals across industries globally, updated in near real-time.
How does Intellizence track M&A deals?
Intellizence continuously monitors trusted global sources, including press releases, regulatory filings, stock exchange disclosures, company announcements, and credible news wires. Each deal is identified, validated, and structured into a standardized M&A signal.
Why is M&A activity surging across so many different sectors simultaneously?
Several macro forces converge to create M&A waves: interest rate cycles (lower rates make deal financing cheaper), post-pandemic strategic resets, pressure from investors for growth, and technological disruption that makes organic expansion slower than acquisition. When corporate balance sheets are healthy and growth opportunities are clear, deals accelerate — and we are seeing that pattern play out across insurance, pharma, mining, biotech, beauty, and food all at once.
How frequently is the data updated?
The dataset is updated near real-time using AI-curated extraction from trusted press wires and credible news sources.
Who uses the Intellizence M&A Dataset?
- Investment and private equity teams
- Corporate strategy and M&A teams
- Sales and business development teams
- Market researchers and analysts
- Risk and competitive intelligence teams
Refreshed Daily